In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leading From The Lab: MIT’s Robert Langer On The Converging Science Of Drugs, Devices And Delivery

"If one has the essential ingredients of a good idea, a patent, data and some talented people, you can often start a company."

Executive Summary

Ten years after our first encounter with MIT’s Robert Langer, In Vivo sits down with the polymath professor – arguably the most inventive and prolific life scientist of his generation – to identify key challenges in medicine. 

You may also be interested in...



Moderna Co-Founder Robert Langer’s Tips For Innovation

Moderna co-founder Robert Langer shared tips to drive innovation at a recent summit, while narrating a fascinating tale of tenacity during the development of angiogenesis inhibitors with Judah Folkman. If an idea is important, it’s sure to be criticized, said the man who has over 1,000 patents issued or pending worldwide.

The Medicines Patent Pool Plots A Post-Pandemic Future: Interview With Director Charles Gore

As the global access debate adapts to the stark inequities exposed by the COVID-19 pandemic, the UN-backed Medicines Patent Pool is emerging as a key player on issues ranging from vaccine tech transfer to making more drugs affordable against the spread of non-communicable diseases like cancer to middle- and low-income countries.

Pacifying A Pandemic With Numbers

Powered by prominent global health philanthropies and the UK’s world-class collaborative capabilities in disease surveillance, the new International COVID-19 Data Alliance (ICODA) is gearing up to address a crucial – and yet unanswered – policy question for public health:  can sharing data curated from a diversity of sources provide the hard evidence needed to improve patient outcomes against the virus – not just for today’s pandemic, but for future ones as well? Much will depend on a robust response from big pharma.

Topics

Related Companies

UsernamePublicRestriction

Register

IV124281

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel